Halozyme Therapeutics (HALO) Tops Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 --0%
Revenue Growth %: +36.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
CAN, UNFI, SUNB, More
Revenue Growth %: +36.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $31.43 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $115-125 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- ICICI Securities Starts Jain Resource Recycling (JAINREC:IN) at Buy (1)
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
